SIGN OUR NEWSLETTER

  • LinkedIn
  • Instagram
  • Facebook
  • Twitter

© 2019 - TissueLabs Pesquisa e Desenvolvimento LTDA - All rights reserved.

CNPJ: 32.624.642/0001-58

Av. Prof. Lineu Prestes, 2242 -  05508-000 - São Paulo, Brazil

+55 11 99286 3570 - info@tissuelabs.com

Delivery time may vary according to the destination. Most of our shipments arrive between 7-21 days.

Supported by:

COVID-19

TissueLabs will distribute, free of charge, an air-liquid platform for in vitro studies on the coronavirus

(2019-nCoV) in the lung epithelium.

The coronavirus pandemic has forced several sectors of society to interrupt their activities, in many cases indefinitely. The quarantine now practiced by countless countries in the world has, however, had its economic sustainability questioned. If the quarantine time practiced by government authorities is reduced or insufficient to eliminate the virus that causes COVID-19, we must be prepared for new spreading waves of the disease. Despite studies on the efficacy of existing drugs, there is and will be an urgent need for the scientific community to rapidly expand its knowledge about the new coronavirus (2019-nCoV) and potential therapeutic targets. 

The current platforms available for in vitro investigation of the coronavirus in the pulmonary epithelium are not representative of the tissue found in the human lung. In general, two-dimensional cultures, traditionally used in biomedical research, subject cells to a microenvironment that is very distinct from that found in the body. Ultimately, this leads to hundreds of new compounds being subjected to pre-clinical and clinical tests, with a low success rate, wasting resources that could be applied to the development of compounds with a higher chance of success. 

With this worrying scenario in mind, TissueLabs turned their whole team to urgently developed a platform for the in vitro study of the 2019-nCoV in the lung epithelium, which is affected during the disease process. This platform contains the extracellular matrix from the lungs, just as cells would find in patients' organs. The researcher is free to personalize the type and origin of the cells to be used with the platform. It means, for instance, that it would be possible to use cells from patients with other comorbidities, such as asthma and COPD, to create personalized 3D tissues. 

The platform will be distributed free of charge to researchers developing studies on the new coronavirus. To request it, researchers must complete the application form below.

Request your platform for FREE!